3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
1270
Specimen Handling
870
Carboplatin
831
Magnetic Resonance Spectroscopy
808
Cyclophosphamide
802
Cisplatin
728
Nivolumab
658
Paclitaxel
631
Radiotherapy
573
Gemcitabine
572
Biopsy
529
Bevacizumab
475
Dexamethasone
440
fludarabine
407
Docetaxel
378
venetoclax
370
Oxaliplatin
365
Capecitabine
356
Fluorouracil
354
atezolizumab
341
durvalumab
334
Rituximab
332
Doxorubicin
316
Radiosurgery
309
Pemetrexed
305
Drug Therapy
302
Ipilimumab
294
Standard of Care
293
Etoposide
285
Radiation
279
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
N(4)-oleylcytosine arabinoside
×
1 year
×
Clear all
NCT05498428
2026-05-08
PALOMA-2
Janssen Research & Development, LLC
Phase 2
Recruiting
520 enrolled
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled